Psychotic Disorder Treatment Market

Psychotic Disorder Treatment Market Outlook (2022-2032)

At present, the global psychotic disorder treatment market accounts for US$ 13.6 billion and is projected to surge past a valuation of US$ 24.5 billion by the end of 2032.

Stress levels among the general population have increased notably over the past few years and this has led to an increase in the incidence of psychotic disorders such as bipolar disorder, schizophrenia, etc.

Fact.MR forecasts worldwide revenue from psychotic disorder treatment to increase at a high CAGR of 6.1% between 2022 and 2032.

Report Attributes	Details
Market Size (2022E)	US$ 13.6 Billion
Forecasted Market Value (2032F)	US$ 24.58 Billion
Global Market Growth Rate (2022-2032)	6.1% CAGR
North America Market Share (2022)	21.3%
Europe Market Share (2022)	25.4%
Key Companies Profiled	Teva Pharmaceutical Industries Ltd. Amgen Inc. Pfizer Inc. Novartis International AG Merck & Co. Inc. Sanofi S.A. Allergan Plc Mylan N.V. Johnson & Johnson Services Inc. F. Hoffmann-La Roche Ltd.

Psychotic Disorder Treatment Demand Analysis (2017-2021) in Comparison to Market Forecasts (2022-2032)

Instances of people suffering from severe psychotic disorders and mental illnesses have been witnessing an increase over the past few years and are projected to follow the same trend throughout the forecast period.

Awareness of psychotic disorders and other mental disorders is increasing with government initiatives and efforts taken by health organizations to capably deal with the increasing caseload of mental disorder patients.

Changes in lifestyle, the prevalence of stress-inducing global and economic conditions, high-stress environments, early onset of mental disorders in teenagers, and increasing prevalence of depression are other factors that could drive demand for psychotic disorder treatment equipment and drugs across the forecast period.

Difficulty in winning approvals from regulatory authorities for new drugs and treatments is expected to discourage psychotic disorder drug manufacturers and have an adverse effect on market growth.

The psychotic disorder treatment market is anticipated to expand at a CAGR of 6.1% through 2032.

What Determinants are Influencing Psychotic Disorder Treatment Market Potential?

“Increasing Investments in R&D of Novel Treatment Drugs & Therapies”

The incidence of severe psychotic disorders has risen over the past few years owing to increased levels of stress in the general population. This has fuelled demand for schizoaffective treatment, bipolar disorder treatment, paranoid schizophrenia treatment, etc.

To find new therapies and treatments for these psychotic disorders healthcare organizations are investing heavily in research and development activities.

“Side Effects of Psychotic Disorder Drugs Denting Market Demand”

Psychotic disorder drugs have been known to have adverse effects after long-term use and this is expected to have a restraining effect on the overall market growth. The lack of availability of certain specific drugs for the treatment of psychotic disorder symptoms is also expected to have a negative impact on the market over the coming years.

Lack of awareness of psychosis treatment procedures among the general population is also expected to constrain market potential through 2032.

What Could Upcoming Psychotic Disorder Treatment Providers Do to Boost Their Business Potential?

“New Market Entrants Can focus on Development of Novel Treatment Procedures & Drugs”

• OxfordVR, a British start-up founded by Deepak Gopalakrishna in 2016, was recently granted a Breakthrough Device designation by the U.S. FDA (Food and Drug Administration) for its treatment of serious mental illnesses such as schizophrenia. The novel treatment utilizes VR (virtual reality) headsets to guide patients through everyday scenarios that could induce anxiety in those suffering from psychosis.

New entrants can create novel therapies and treatment solutions for psychotic disorder symptoms and carve out a chunk of the market share for themselves by disrupting the global psychotic disorder treatment industry landscape.

Cognitive-behavioral therapy for psychosis has been a popular psychotic disorder treatment over the past years and new market players could enhance this therapy by improving its treatment by investing more in its research. They could also invest in research to develop a completely novel therapy for the treatment of mental illnesses.

Which Regions Should Psychotic Disorder Treatment Providers Focus On?

“Demand for Psychotic Disorder Treatment Highest in Europe”

The Europe psychotic disorder treatment market accounts for a total valuation of US$ 3.45 billion in 2022 and holds a notable market share of 25.4% in the global industry landscape.

Increasing prevalence of severe psychotic disorders and rising awareness of mental health issues are prime factors driving market growth in this region.

Surging cases of severe mental illnesses and rising focus on mental health in North America are anticipated to primarily propel psychotic disorder treatment demand in this region. Currently, the market in the region accounts for a sales revenue of US$ 2.89 billion and a market share of 21.3%.

Initiatives to increase awareness of mental health disorders and the early onset of mental health issues such as depression and OCD (Obsessive -compulsive disorder) are expected to drive psychotic disorder treatment market growth in the Asia Pacific region.

Homeopathic medicines for psychosis and natural medicines for psychotic depression are anticipated to witness a steady increase in demand through 2032.

Fact.MR, a market research and competitive intelligence provider has listed a complete regional assessment of the psychotic disorder treatment market in this latest research study.

Competitive Landscape

Psychotic disorder treatment providers are pushing for the approval of new drugs and treatment therapies from regulatory bodies to fast-track the launch of these novel treatments.

• In February 2022, AbbVie, a leading biopharmaceutical organization, announced that it had submitted a Supplemental New Drug Application to the United States Food and Drug Administration (FDA). The application is based on new clinical trial results for cariprazine (VRAYLAR®) for adjunctive treatment of major depressive disorder (MDD).
• In April 2022, BioXcel Therapeutics, a renowned biopharmaceutical firm, announced that it had received approval for IGALMI™ (dexmedetomidine) Sublingual Film by the U.S. FDA, which will be used to treat bipolar disorder.

Segmentation of Psychotic Disorder Treatment Industry Research

• By Drug Type :

  • Atypical Antipsychotics
  • Phenothiazine Antipsychotics
  • Thioxanthenes
  • Miscellaneous Antipsychotics Agents

• By Indication :

  • Schizophrenia
  • Bipolar Disorder
  • Delusional Disorder
  • Drug Induced Psychosis
  • Organic Psychosis

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • e-Commerce

• By Region :

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA